OSTEOMET project
Prostate Cancer OSTEOMET
clinical utility of OSTEOMET
positioning OSTEOMET
commercialization of OSTEOMET
clinical validation track
clinical practice
clinical validation studies
business feasibility of marketing OSTEOMET
Prediction of Bone Metastasis
risk of bone metastasis
Early Stage Breast
US market
market penetration
proposal
phase
current project
new diagnostic kit
Novel Biomarker
existing gaps
number of scenarios
different scenarios
personalized therapy of patients
innovative single biomarker
elaborated business plan
strategic approach
expression levels
improved prognosis
various aspects
regulatory path
drive clinician adoption
payer acceptance
reimbursement environment
FISH technologies
assessment
EU
primary tumour tissue
large positive impact
proprietary test
target user specifications
economic efficiency of health care operators
unmet medical need
IHC
strategy
improvement
value
expert interviews
Pharma companies
partnerships
clear roadmap
outcome
threshold
Inbiomotion
step
criterion